Antibiotics specialist Bioversys reported Phase IIa early bactericidal activity for alpibectir (BVL‑GSK098) in combination with ethionamide for pulmonary tuberculosis, with findings published in the New England Journal of Medicine. The data demonstrate potential to potentiate ethionamide and overcome drug resistance mechanisms in Mycobacterium tuberculosis. TB drug development targets shortening regimens and tackling resistant strains; a positive signal in early bactericidal activity (EBA) supports further clinical testing toward that goal.